Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

HALOBETASOL PROPIONATE

All products: general benefit

Other products in the same Health Canada class (D07AC) — coverage varies; not interchangeable

  • Amcinonide (Cyclocort): general benefit, Not a benefit
  • Beclomethasone dipropionate (Propaderm): general benefit
  • Betamethasone dipropionate (Diprosone): general benefit
  • Betamethasone dipropionate in a base containing propylene glycol (Diprolene): general benefit
  • Betamethasone dipropionate in propylene glycol base (Diprolene Glycol): general benefit
  • Betamethasone valerate (Betnovate-1/2): general benefit, Not a benefit

8 more in the class list below

Bryhali · DIN 02506262 · 0.01% w/w · Lot

General benefitMarketed · checked 2026-09-19
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Bryhali · DIN 02506262 Manufacturer: Bausch Health Canada Inc.; listing date 2023-04-28 Health Canada: Marketed since 2021-08-06 · brand BRYHALI · ATC D07AC21 ULOBETASOL · form Lotion · route Topical · ingredients HALOBETASOL PROPIONATE 0.01 %/W/W · company Bausch health, canada inc. · schedule Prescription
Check this DIN again · Health Canada product record

Bryhali: Formulary list price $0.9816/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.9816 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99560 · Verify on the e-Formulary ↗ (DIN 02506262)

Source record
DIN 02506262: Bryhali Raw flags: sec3=Y Item: 840600156; group id 845; item number 2058; lccId None; manufacturer id BHC Source form: Lot; strength: 0.01% w/w Recorded listing: General benefit Source prices (unrounded): $0.9816; ministry $0.9816 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02506262 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99560 Therapeutic Notes (formulary) No more than 50 grams per week is recommended.
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (84:06 Anti-Inflammatory) and how they are covered

Matched class: 84:06 Anti-Inflammatory

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BECLOMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE IN A BASE CONTAINING PROPYLENE GLYCOL, BETAMETHASONE DIPROPIONATE IN PROPYLENE GLYCOL BASE, CALCIPOTRIOL & BETAMETHASONE DIPROPIONATE, MOMETASONE FUROATE Some products covered without a code (check the product listing): AMCINONIDE, BETAMETHASONE DIPROPIONATE, BETAMETHASONE VALERATE, CLOBETASOL PROPIONATE, DESONIDE, FLUOCINONIDE, HYDROCORTISONE, HYDROCORTISONE ACETATE, HYDROCORTISONE VALERATE, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE 0.1% IN ORABASE 84:06 Anti-Inflammatory

AMCINONIDE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 0.1% · Cr

BECLOMETHASONE DIPROPIONATE

· 2 products · General benefit · strengths: 0.025% · Cr, Oint

BETAMETHASONE DIPROPIONATE

· 6 products · General benefit (5), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1) · strengths: 0.05% · Cr, Lot, Oint

BETAMETHASONE DIPROPIONATE IN A BASE CONTAINING PROPYLENE GLYCOL

· 2 products · General benefit · strengths: 0.05% · Oint

BETAMETHASONE DIPROPIONATE IN PROPYLENE GLYCOL BASE

· 2 products · General benefit · strengths: 0.05% · Cr

BETAMETHASONE VALERATE

· 19 products · Listed, not a benefit (7), General benefit (12) · strengths: 0.05%, 0.1% · Cr, Lot, Oint, Scalp Lot

FLUOCINONIDE

· 8 products · General benefit (4), Listed, not a benefit (4) · strengths: 0.05% · Cr, Emol Cr, Gel, Oint

MOMETASONE FUROATE

· 6 products · General benefit · strengths: 0.1% · Cr, Lot, Oint

CLOBETASOL PROPIONATE

· 20 products · General benefit (11), Off-Formulary Interchangeable, not an ODB benefit (9) · strengths: 0.05%, 0.05% w/w · Cr, Oint, Scalp Lot, Top Shampoo, Top Sol Sp

DESONIDE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 0.05% · Cr, Oint

HYDROCORTISONE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 0.5%, 1% · Oint

HYDROCORTISONE ACETATE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 1% · Cr Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 84:06 and 5 more
Full class listing Related classes: 84:04 Anti-Infectives, 84:28 Keratolytic Agents, 84:36 Miscellaneous Skin and Mucous Membrane Agents Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS BRYHALI (halobetasol propionate) is a high to super-high potency topical corticosteroid indicated for corticosteroid-responsive dermatoses and the topical treatment of plaque psoriasis. 1.1 Pediatrics Pediatrics (< 18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics Geriatrics (≥ 65 years of age): A limited number of subjects aged ≥ 65 years have been treated with BRYHALI in clinical trials, therefore the safety and efficacy have not been established in this patient population (see 7.1.4 Geriatrics). https://pdf.hres.ca/dpd_pm/00072042.PDF PM date: August 14, 2023 Source product: BRYHALI; DIN 02506262; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.